Sigyn Therapeutics (Sigyn Therapeutics) Debt-to-Equity : -0.66 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Debt-to-Equity?

Sigyn Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.54 Mil. Sigyn Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.11 Mil. Sigyn Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-4.02 Mil. Sigyn Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was -0.66.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sigyn Therapeutics's Debt-to-Equity or its related term are showing as below:

SIGY' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.23 Med: -0.68 Max: 5.24
Current: -0.66

During the past 10 years, the highest Debt-to-Equity Ratio of Sigyn Therapeutics was 5.24. The lowest was -7.23. And the median was -0.68.

SIGY's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs SIGY: -0.66

Sigyn Therapeutics Debt-to-Equity Historical Data

The historical data trend for Sigyn Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics Debt-to-Equity Chart

Sigyn Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.77

5.24

-3.53

-0.99

-0.70

Sigyn Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-1.15	-0.94	-0.88	-0.70	-0.66

Competitive Comparison of Sigyn Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Sigyn Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sigyn Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's Debt-to-Equity falls into.

Sigyn Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sigyn Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.271	+	0.126)	/	-3.413
	=	-0.70

Sigyn Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.54	+	0.11)	/	-4.021
	=	-0.66

Sigyn Therapeutics (OTCPK:SIGY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sigyn Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigyn Therapeutics (Sigyn Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106

Website

https://www.sigyntherapeutics.com

Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

Executives

Joseph Segelman	director, 10 percent owner, officer: President & CEO	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp	10 percent owner	9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman	director, officer: Secretary	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212